Latest Patient Engagement News

HeraMED is fast-tracking its AI-driven maternity care technologies, including an early release of its AI Clinician Assistant and predictive models for high-risk pregnancies, aiming to revolutionize digital women’s health globally.

Adherium Limited’s iCARE study reports unprecedented medication adherence improvements and sustained patient engagement in COPD and asthma care, highlighting significant clinical and economic benefits.

LTR Pharma’s FY25 results reveal a transformative year highlighted by SPONTAN’s rapid absorption and strategic partnerships that pave the way for US market entry.

Telix Pharmaceuticals has received a Complete Response Letter from the FDA for its TLX250-CDx diagnostic agent, citing manufacturing concerns. The company plans immediate remediation and maintains its 2025 revenue guidance.

Vitasora Health has expanded its partnership with Tampa Family Health Centers to deliver chronic care and remote monitoring services to 7,000 Medicaid patients, unlocking over US$4 million in annual revenue. This marks a pioneering step for Florida’s largest Federally Qualified Health Center in adopting value-based care for underserved communities.

Oneview Healthcare reported a robust 36% revenue increase in H1 2025, driven by US market growth and the launch of its AI-powered Care Assistant, Ovie. Operational restructuring and AI innovation underpin its strategy for scalable, efficient deployments.

Oneview Healthcare PLC reported a 36% increase in revenue for the first half of 2025, driven by strong deployment activity and new US customers, while managing a wider net loss due to FX impacts and restructuring costs.

ResMed Inc. reported a robust 10% increase in revenue to $5.15 billion for fiscal 2025, driven by strong demand in sleep and breathing health devices and residential care software. The company also expanded its diagnostic capabilities with the acquisition of VirtuOx, positioning itself for further growth in home-based health solutions.

Botanix Pharmaceuticals confirms material sales and prescription growth data, explaining the timing of its ASX disclosures amid share price fluctuations.

MedAdvisor Solutions reported a 16.6% revenue decline in 4Q FY25, driven by US market challenges, while completing the sale of its ANZ business and initiating a strategic review of its US operations.

MedAdvisor reports a significant revenue decline in FY25 amid US program delays but strengthens its balance sheet through a capital raise and ANZ business sale. The company signals a strategic pivot with potential US business divestment on the horizon.

Doctor Care Anywhere has reported a landmark positive operating and investing cash inflow in Q2 2025, alongside modest consultation growth and strategic service expansion. The company reiterates its ambitious revenue and profitability targets amid ongoing cost transformation.